Skip navigation

Body Flex charged with false claims

FTC files lawsuit against maker of weight-loss product

Diet and fitness videos
Make more healthy swaps at restaurants
  Dec. 8: Do you know which omelet is as bad for you as 11 scoops of ice cream? Men’s Health magazine’s David Zinczenko has tips for making better choices at restaurants from his newest book in his “Eat This Not That!” series.

  Smart Fitness — By Jacqueline Stenson
Image: Woman running in snow
Getty Images stock
Can exercise help ward off the swine flu?
Studies have concluded that exercise can enhance the immune system, but is the effect great enough to stave off swine flu?

WASHINGTON, Nov. 10 - The government charges that Body Flex, a weight-loss program featured in television infomercials, does not help users quickly lose fat and inches off their waists, contrary to its claims. The Federal Trade Commission filed a lawsuit against Body Flex on Monday in U.S. District Court in Los Angeles, saying the company made claims that aren’t true.

Body Flex spent $22 million this year to air its infomercial more than 2,000 times, claiming its program, which involves a breathing regiment and exercises with a plastic bar and elastic band, will help users drop four to 14 inches across six body areas in a week. The company says the routine could be done sitting down in 18 to 20 minutes a day.

“These claims of fast, easy inch loss without diet or exercise exploit the millions of overweight Americans looking for an effective weight-loss and exercise program,” said Howard Beales, consumer protection bureau director. “Frankly, we think Body Flex’s breathtaking claims are full of hot air.”

Story continues below ↓
advertisement | your ad here

Joe Costa, lawyer for the California companies that market Body Flex, Savvier Inc. and Savvier LP, said the product has been sold for 10 years to customers who love it.

“To the best of our knowledge, the FTC has not yet had an opportunity to review the substantiation and the studies supporting the Body Flex products,” Costa said. “We look forward to working with the FTC in providing them with this information and are confident that once the FTC has fully had an opportunity to review and analyze the clinical substantiation for this product, the situation will be resolved.”

© 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Resource guide